WEDNESDAY, April 4 (HealthDay News) ? There appears to be a link
between an injectable form of progestin-only birth control, best known as
Depo-Provera, and an increased risk of breast cancer in young women, new
research suggests.
For the study, researchers compared more than 1,000 Seattle-area women,
aged 20 to 44, who were diagnosed with breast cancer, and more than 900
women without breast cancer.
Recent use of the injectable contraceptive (formally called
depo-medroxyprogesterone acetate or DMPA) for a year or longer was
associated with a 2.2-fold increased risk of invasive breast cancer, the
study found.
This increased risk appeared to fade within months after women stopped
using the contraceptive, and women who used the contraceptive for less
than a year or who had stopped using it more than a year earlier did not
have any increased risk of breast cancer, according to the findings
published online and in the April 15 print issue of the journal Cancer
Research.
?Although breast cancer is rare among young women and the elevated risk
of breast cancer associated with DMPA appears to dissipate after
discontinuation of use, our findings emphasize the importance of
identifying the potential risks associated with specific forms of
contraceptives given the number of available alternatives,? study leader
Dr. Christopher Li, a breast cancer epidemiologist at the Fred Hutchinson
Cancer Research Center in Seattle, and colleagues wrote.
?In the United States, many women have numerous options for
contraception, and so it is important to balance their risks and benefits
when making contraceptive choices,? Li noted in a news release from the
research center.
While the study uncovered an association between Depo-Provera and
raised breast cancer risk, it could not prove a cause-and-effect
relationship.
Commenting on the study, Dr. Elizabeth Poynor, a gynecologic oncologist
and pelvic surgeon at Lenox Hill Hospital in New York City, said, ?This
study further confirms that some types of progestins are not healthy for
the breast. For women who are at elevated risk to develop breast cancer
based on family history, or even age, this type of contraception may not
be a good choice for them.?
But another expert cautioned that the study did have its limits.
Dr. Freya Schnabel, director of breast surgery at NYU Clinical Cancer
Center in New York City, noted that the women in the study who seemed at
highest risk of developing breast cancer while on Depo-Provera were those
with a family history of the disease or women who had never had children
(another known risk factor).
Furthermore, she said, ?the study did not include information about all
breast cancer risk factors in the participants, and this is a real
limitation of the analysis which could impact on the results. Also, the
mechanism by which the progesterone would increase risk only in current
users is not clear.?
According to Schnabel, all of this means that ?more detailed studies
are needed to clarify the relationship between this contraceptive method
and risk of breast cancer.?
The research was funded by the U.S. National Cancer Institute and the
Department of Defense Breast Cancer Research Program.
More information
Planned Parenthood has more about the birth control shot.
best buy black friday 2011 ads broncos jets jessie james osu basketball dale sveum jets broncos thursday night football
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.